NEW YORK (GenomeWeb News) – MDxHealth today reported a roughly 53 percent increase in its first-quarter revenues year over year driven by sales of its prostate cancer molecular test.

The Liege, Belgium-based firm said that total revenues for the three months ended March 31 were €1.1 million ($1.4 million), up from €719,000 for the first quarter of 2012. All of its revenues were derived from commercial product and service sales. The first quarter of last year included €137,000 in grant revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.